Treatment of an Older Patient with Early-Stage, HER2-Positive Breast Cancer


This case-based course details the multi-step process of treatment decision-making for an older woman with early-stage, HER2-positive and hormone receptor-positive breast cancer. Life expectancy estimation, goals of treatment and calculation of treatment benefits and toxicities are explored in the context of shared clinician-patient decision making.

Learning Objectives

Upon participation in this activity, learners will be better able to:

  • Based on patient and disease factors, select the most appropriate therapy for an older patient with early-stage, hormone receptor-positive, HER2-positive breast cancer.

Certificate Available


Hyman B. Muss, MD, FASCO
University of North Carolina/Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Disclosure of Relationships with Companies

Financial relationships reported by course faculty, planners, and reviewers (F = Faculty, P = Planner, R = Reviewer).
During all phases of planning and development, areas of conflict were managed through a peer-review process and/or through individual recusal when appropriate. All relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution).

Hyman B. Muss, MD (F): No relationships to disclose

Helen K. Chew, MD (P, R): Honoraria - Novartis
Tyler Paul Johnson, MD (P, R): Employment -; Other Relationship - Heme/Onc Questions

Commercial Support

This activity was supported by ASCO eLearning. No funds or in-kind contributions from commercial entities were used for support.

Disclaimer / Unlabeled Usage Statement

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

This site is intended for healthcare professionals in Europe and Japan only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2023 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

Before you go....

We'd love your feedback!

Your feedback will help guide us in the next phase of this program. Please take a few minutes (estimated 2 minutes) to answer the following 6 questions.